Ifosfamide Encephalopathy
- 1 January 1989
- journal article
- research article
- Published by Taylor & Francis in Journal of Toxicology: Clinical Toxicology
- Vol. 27 (4-5) , 293-298
- https://doi.org/10.3109/15563658908994426
Abstract
We describe a case of reversible encephalopathy caused by the recently released anticancer drug Ifosfamide. The clinical course, role of EEG in monitoring and predicting encephalopathy, and putative mechanism of neurotoxicity is discussed. Short infusion times and/or prior CNS disease may increase the risk of encephalopathy.This publication has 8 references indexed in Scilit:
- Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumorsJournal of Neuro-Oncology, 1988
- ENCEPHALOPATHY WITH RAPID INFUSION IFOSFAMIDE/MESNAThe Lancet, 1987
- DECHLOROETHYLATION OF IFOSFAMIDE AND NEUROTOXICITYThe Lancet, 1986
- AVOIDING IFOSFAMIDE/MESNA ENCEPHALOPATHYThe Lancet, 1986
- Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.Journal of Clinical Oncology, 1986
- Prediction of Ifosfamide/Mesna associated encephalopathyEuropean Journal of Cancer and Clinical Oncology, 1986
- ENCEPHALOPATHY ASSOCIATED WITH IFOSPHAMIDE/MESNA THERAPYThe Lancet, 1985
- Central nervous side effects following ifosfamide monotherapy of advanced renal carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 1981